American Electric Power Company Inc
Change company Symbol lookup
Select an option...
AEP American Electric Power Company Inc
BAF BlackRock Municipal Income Investment Quality Trust
HRTH Harte Hanks Inc
STRA Strategic Education Inc
TFECY Thin Film Electronics ASA
ELY Callaway Golf Co
WBA Walgreens Boots Alliance Inc
GOOG Alphabet Inc
CUB Cubic Corp
BAC Bank of America Corp

Utilities : Electric Utilities | Large Cap Value
Company profile

American Electric Power Company, Inc. (AEP) is a public utility holding company that owns, directly or indirectly, all of the outstanding common stock of its public utility subsidiaries and varying percentages of other subsidiaries. The service areas of the Company's public utility subsidiaries cover the states of Arkansas, Indiana, Kentucky, Louisiana, Michigan, Ohio, Oklahoma, Tennessee, Texas, Virginia and West Virginia. The Company's segments include Vertically Integrated Utilities, Transmission and Distribution Utilities, AEP Transmission Holdco, and Generation & Marketing. AEP's vertically integrated utility operations are engaged in the generation, transmission and distribution of electricity for sale to retail and wholesale customers. Transmission and Distribution Utilities segment consists of the transmission and distribution of electricity for sale to retail and wholesale customers. AEP Transmission Holdco develops, constructs and operates transmission facilities.

Closing Price
Day's Change
0.55 (0.65%)
B/A Size
Day's High
Day's Low

10-day average volume:

Dexcom Signs Multi-Year Collaboration Agreement with the University of Virginia to Advance Type 1 and Type 2 Diabetes Research

8:30 am ET September 24, 2020 (BusinessWire) Print

DexCom, Inc. (NASDAQ:DXCM) today announced it has signed a five-year collaboration agreement with the University of Virginia to advance its research and development efforts on continuous glucose monitoring-based solutions. The research partnership will center on advancing Dexcom's automated insulin delivery technology and exploring the use of continuous glucose monitoring tools outside the Type 1 diabetes market, including inpatient hospital use, Type 2 diabetes and gestational diabetes.

The collaboration will expand upon Dexcom's automated insulin delivery technology, which the company acquired in 2018 with the purchase of Virginia-based startup TypeZero Technologies and the establishment of Dexcom's Charlottesville office. In addition, the company's next-generation closed loop algorithms will be refined and piloted in a series of clinical trials. The expansion of Dexcom's Charlottesville team in conjunction with the research collaboration with the University of Virginia are important steps to accelerate and broaden the Company's analytic capabilities and innovations in these disciplines.

The University of Virginia's Center for Diabetes Technology will spearhead the research efforts, led by Drs. Boris Kovatchev and Marc Breton. The collaboration is also designed to engage multiple disciplines and schools across the University of Virginia system, including the School of Engineering, the School of Data Science and the School of Medicine. Dexcom and the University of Virginia have a long history of research and clinical collaboration, including the recent International Diabetes Closed Loop trial (iDCL).

"Dexcom is committed to bringing innovative continuous glucose monitoring-based solutions to empower customers and clinicians toward greater health outcomes," said Kevin Sayer, chairman, president and chief executive officer of Dexcom. "We are investing heavily in research and development efforts that explore new diagnostic tools and treatments. By partnering with a top-tier research institution like the University of Virginia, we hope to bring better CGM solutions to patients much faster than we could alone."

"The University of Virginia has become one of the world's leading research institutes for diabetes technology," said Jim Ryan, president of the University of Virginia. "This expanded commitment from Dexcom ensures that research conducted on Grounds has a clear path to enrich and improve the lives of patients and caregivers managing this complicated and all too common disease."

The partnership will commence in late 2020 and Dexcom will provide research funding to the University of Virginia over a five-year period for diabetes-centered research and clinical trials.

About DexCom, Inc.

DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world.

View source version on

SOURCE: DexCom, Inc.

Media Contact: 
James McIntosh, (619) 884-2118
Dexcom Public Relations

Investor Contact: 
Steve Pacelli, (858) 200-0200
Dexcom Strategy and Corporate Development
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.